|SR-33805 is a calcium channel antagonist potentially for the treatment of atherosclerosis and heart failure. SR-33805 restored the MI-altered cell shortening without affecting the Ca(2+) transient amplitude, suggesting an increase of myofilament Ca(2+) sensitivity in MI myocytes. A SR33805-induced sensitization of myofilament activation was found to be associated with a slight increase in myosin light chain-2 phosphorylation and a more significant decrease on troponin I (TnI) phosphorylation. Decreased TnI phosphorylation was related to inhibition of protein kinase A activity by SR-33805.
|SR33805 是钙通道拮抗剂，在去极化和极化条件下的 EC50值分别为 4.1 和 33 nM。它阻止 L 型 Ca2+通道，可用于研究急性或慢性心脏衰竭。
|Ca2+ channel antagonist
|CGS 21595 inhibits the formation of 5-hydroxyeicosatetraenoic acid and leukotriene B4; rapidly metabolized to CGS 19213.